SCHEMBL3295362

SCHEMBL3295362

Cc1cc(Nc2ccnc(Nc3ccc(S(=O)(=O)N4CCC(C(O)c5ccncc5)CC4)cc3)n2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 10/20 0.44
CHUK O15111 9/20 0.44
CDK2 P24941 3/20 0.43
CCNE1 P24864 2/20 0.43
CDK4 P11802 1/20 0.43
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SYK P43405 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3C2G O75747 1/20 0.37
PIK3CG P48736 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
AURKA O14965 1/20 0.37
MAP4K4 O95819 1/20 0.37
PIM1 P11309 1/20 0.37
MAPK8 P45983 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13392092 1.00 IKBKB (0.44) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL13392293 0.92 IKBKB (0.42) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3300337 0.92 IKBKB (0.42) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL14095890 0.91 IKBKB (0.46) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3298041 0.91 IKBKB (0.43) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL13392089 0.91 IKBKB (0.43) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL13844896 0.90 IKBKB (0.42) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3306513 0.86 IKBKB (0.51) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL13392369 0.86 CDK4 (0.44) IKBKBCHUKCDK2CCNE1CDK4
SCHEMBL3302095 0.86 CDK2 (0.45) IKBKBCHUKCDK2CCNE1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
EP-2118092-A1 NEW N, N'- 2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS Sanofi-Aventis (FR) 2009-11-18 EP disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
WO-2008099073-A1 N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF SANOFI-AVENTIS (FR) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE IKBKB 2/4885CHUK 1/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.